anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Since the onset of pandemic conditions in 2020 and the increase of lockdowns, almost all rehabilitation programs for MS patients in Iran were suspended, it is necessary to study the effects of home-based cognitive and physical interventions to improve executive functions and anxiety in MS patients. The present study will be conducted to investigate the effects of home-based Pilates exercises and the combination of home-based Pilates exercises with home-based cognitive rehabilitation as well as to compare the effects of these two interventions on executive functions and anxiety in MS patients. In this study, participants will be divided into two experimental groups and a control group. The research process and the reason for conducting the research will be explained to the candidates by lead researcher and the final participants will sign the research participation form. All 51 final participants will be identified by a code and their identity information will not be disclosed, and in order to avoid any bias, each code will be randomly divided into three groups randomly. Pre-test will be taken from all three groups before the intervention. Experiment group 1 will perform a home-based Pilates video training program for 8 weeks, two sessions a week at home, and will also pay attention to exercise-related tips for MS patients determined by specialists. At the same time, Experiment group 2 will be asked to perform home-based cognitive rehabilitation program for 8 weeks, 3 seasons a week at home, in addition to home-based Pilates exercises same as experimental group 1. Group 3 will also be on the waiting list as a control group and will not receive any interventions for 8 weeks. At the end of 8 week intervention, Pilates training packages and cognitive exercises will be provided to the control group for their own use. During the 8 weeks of the intervention, the Pilates instructor and the cognitive rehabilitation specialist will contact the subjects on a weekly basis and monitor their performance. Subjects will also be able to contact the researchers and express their questions and problems. Also, they will be able to hold online meetings with research facilitators for solving the problems and educating the exercises. During the 8 weeks of the intervention, if subjects have problems such as COVID-19 affection, coronary heart disease, muscle problems, relapse, and failure to perform more than 4 sessions of exercise, they will be excluded from the study by the lead researcher. In order to fully perform the exercises for people who do not perform up to 4 sessions of exercises, 2 weeks can be added to the intervention period, which will be applied by the lead researcher. After complete implementation of the intervention, post-test will be taken from all 3 groups and the results will be compared to the baseline and relative to each other.
Bendamustine 90 mg/m2 d1-2. Brentuximab vedotin 1.8 mg/kg d1.Every 21 days for 6 cycles.
BACKGROUND: A major challenge in the clinical management of oral cavity squamous cell carcinoma is local relapse. Even when surgical margins are tumor-free, local relapses occur frequently, and relapse prediction by histology remains suboptimal. In leukoplakia, an oral potentially malignant disorder, the presence of architectural dysplasia is a critical risk factor for malignant transformation. This study aimed to investigate whether the presence of architectural dysplasia in oral cavity squamous cell carcinoma surgical margins is a risk factor for local relapse.
METHODS: Hematoxylin and eosin-stained slides of resection margins from a consecutive cohort of surgically treated patients diagnosed with stage I-IV oral cavity squamous cell carcinoma between 2008 and 2014 were assessed for the presence of architectural dysplasia (N = 311). Five-year local relapse-free survival rates of oral cavity squamous cell carcinoma with architectural dysplasia were compared to those of oral cavity squamous cell carcinoma without architectural dysplasia.
RESULTS: In total, 92 of 311 (29.6%) of oral cavity squamous cell carcinoma displayed architectural dysplasia in the margins. The presence of architectural dysplasia was associated with higher patient age, female sex, less pack years, lower cT-stage, and a cohesive tumor growth pattern. In oral cavity squamous cell carcinomas with architectural dysplasia, postoperative (chemo)radiotherapy was less often indicated compared with oral cavity squamous cell carcinoma without architectural dysplasia (19.5% vs. 36.1%, p = 0.009). Five-year local relapse-free survival was significantly lower in oral cavity squamous cell carcinoma with architectural dysplasia than in oral cavity squamous cell carcinoma without architectural dysplasia (83.1% vs. 94.9%, p = 0.017).
CONCLUSIONS: Oral cavity squamous cell carcinoma arising in the background of architectural dysplasia displays relatively favorable clinical and histopathological characteristics. Nonetheless, the presence of architectural dysplasia in oral cavity squamous cell carcinoma surgical margins is associated with a higher risk of local relapse, indicating its clinical relevance.
PURPOSE:To obtain a cosmetic, containing alpha-linolenic acid or a derivative thereof, capable of preventing drying and aging of the skin, roughening and drying of the epidermis, suppressing depilation and dandruff, keeping the clean, young and fresh epidermis and promoting hair production and growth. CONSTITUTION:A cosmetic containing alpha-linolenic acid obtained from linseed oil, perilla oil, perilla seed oil, rapeseed oil, soybean oil, etc., i.e. cis-9,cis-12, cis-15-octadecatrienoic acid, or a derivative thereof (e.g. alpha-linolenic acid DL-alpha- tocopherol) in an amount of preferably about 0.01-20wt.% based on the total weight of the cosmetic base. The cosmetic is capable of keeping the essential fatty acid balance, maintaining physiological function of the skin in a healthy state and enhancing epidermal beautifying effects by using linoleic acid with gamma-linolenic acid together. This cosmetic exercises great effects on formation of healthy and beautiful epidermises.
BACKGROUND: Circular RNAs (CircRNAs) have been shown to be involved in the development of chronic kidney disease (CKD). This study aimed to investigate the role of Circ1647 in renal fibrosis, which is a hallmark of CKD.
METHODS: In this study, we established a unilateral ureteral obstruction (UUO) model and delivered Circ1647 RfxCas13d knockdown plasmid into renal parenchymal cells via retrograde injection through the ureter followed by electroporation. After that, the pathological changes were determined by Hematoxylin and Eosin. Meanwhile, Immunohistochemistry, qRT-PCR and Western blot were conducted to assess the degree of fibrosis. In addition, overexpressing of Circ1647 in renal tubular epithelial cells (TCMK1) was performed to investigate the underlying mechanisms of Circ1647.
RESULTS: Our results displayed that electroporation-mediated knockdown of Circ1647 by RfxCas13d knockdown plasmid significantly inhibited renal fibrosis in UUO mice as evidenced by reduced expression of fibronectin and α-SMA (alpha-smooth muscle actin). Conversely, overexpression of Circ1647 in TCMK1 cells promoted the fibrosis. In terms of mechanism, Circ1647 may mediate the PI3K/AKT Signaling Pathway as demonstrated by the balance of the phosphorylation of PI3K and AKT in vivo and the aggravated phosphorylation of PI3K and AKT in vitro. These observations were corroborated by the effects of the PI3K inhibitor LY294002, which mitigated fibrosis post Circ1647 overexpression.
CONCLUSION: Our study suggests that Circ1647 plays a significant role in renal fibrosis by mediating the PI3K/AKT signaling pathway. RfxCas13d-mediated inhibition of Circ1647 may serve as a therapeutic target for renal fibrosis in CKD.
1. The use of eletriptan, or of a pharmaceutically acceptable salt or composition thereof, for the manufacture of a medicament for the prevention of migraine recurrence. 2. Use as claimed in claim 1 wherein the salt is a hydrobromide salt. 3. Use as claimed in claim 1 wherein the salt is a hemisulphate salt. 4. Use as claimed in claim 1 wherein the medicament comprises eletriptan hemisulphate and caffeine. 5. Use as claimed in claim 1 wherein the medicament comprises eletriptan, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. 6. Use as claimed in claim 1 wherein the medicament is a dual-, sustained-, controlled-, delayed- or pulsed-release formulation of eletriptan or a pharmaceutically acceptable salt thereof. 7. Use as claimed in claim 6 wherein the medicament is a dual-release formulation of eletriptan or a pharmaceutically acceptable salt thereof. 8. A method for preventing of migraine recurrence comprising administering a patient in need an effective amount of eletriptan, or a pharmaceutically acceptable salt or composition thereof. 9. The method as claimed in claim 8 wherein the salt is a hydrobromide salt. 10. The method as claimed in claim 8 wherein the salt is a hemisulphate salt. 11. The method as claimed in claim 8 wherein the composition comprises eletriptan hemisulphate and caffeine. 12. The method as claimed in claim 8 wherein the composition comprises eletriptan, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. 13. The method as claimed in claim 8 wherein the composition is a dual-, sustained-, controlled-, delayed- or pulsed-release formulation of eletriptan or a pharmaceutically acceptable salt thereof. 14. The method as claimed in claim 8 wherein the composition is a dual-release formulation of eletriptan or a pharmaceutically acceptable salt thereof.
A method of treating or preventing a disease or condition in a subject that was previously treated with at least one thienopyhdine is described. The method includes administering to the subject an effective amount of at least one reversible, short-acting P2Yi2 inhibitor. The described method can be used for subjects diagnosed with symptoms such as stable or unstable angina, vascular ischemic events, atherosclerosis, acute coronary syndrome, as well as STEMi or N-STEMI. The described method can also be used for patients having previously received a stent, such as a bare metal stent or a drug-eluting stent, and the treatment or prevention of stent thrombosis. The method can be used prior to, during, or after an invasive procedure such as coronary artery bypass grafting, percutaneous coronary intervention, or other genera! surgical procedure.
Ischemic stroke occurs due a blockage in the blood flow to the brain, leading to damage to the nervous system. The prevalent morbidities resulting from stroke include post-stroke infection, as sepsis. Additionally, oxidative stress is recognized for inducing functional deficits in peripheral organs during sepsis. Therefore, sex differences in stroke exist and we aimed to investigate the peripheral oxidative stress caused by sepsis after stroke in male and female rats. Wistar rats (male and female) were divided into sham+sham, middle cerebral artery occlusion (MCAO) + sham, sham+ cecal ligation and perforation (CLP) and MCAO+CLP groups to males and female rats. Animals were subjected to MCAO or sham and after 7 days, were subjected to sepsis by CLP or sham. After 24 h, serum, total brain, lung, liver, heart, and spleen were collected. Brain edema, myeloperoxidase (MPO) activity, nitrite/nitrate (N/N) concentration, oxidative damage to lipids and proteins, and catalase activity were evaluated. Brain edema was observed only in male rats in MCAO+CLP group compared to MCAO+sham. Regarding MPO activity, an increase was verified in male in different organs and serum in MCAO+CLP group. For N/N levels, the increase was more pronounced in females submitted to MCAO+CLP. In general, to oxidative stress, an increase was only observed in animals exposed to MCAO+CLP, or with a greater increase in this group compared to the others. The findings provided the first indication that animals exposed to MCAO exhibit a heightened vulnerability to the harmful impacts of sepsis, as evidenced by brain edema and peripheral oxidative stress, and this susceptibility is dependent of sex.
OBJECTIVE: Chronic venous disease is a common condition and has a significant impact on patients' health status. Validated patient-reported outcome measures (PROMs) used to assess health status are needed to measure health status. This state-of-the-art review summarizes the current validation evidence for disease-specific PROMs for chronic venous disease and provides a framework for their use in the clinical setting.
METHODS: A literature search in OVID Embase and Medline was conducted to identify relevant English-language studies of chronic venous disease that used disease-specific PROMs between January 1, 1993, and June 30, 2022. Abstracts and titles from identified studies were screened by four investigators, and full-text articles were subsequently screened for eligibility. Data on validation of disease-specific PROMs was abstracted from each included article. Classical test theory was used as a framework to examine a priori defined validation criteria for content validity, reliability (construct validity, internal reliability, and test-retest reliability), responsiveness, and expansion of the validation evidence base (use in randomized controlled trials and comparative effectiveness research, cultural or linguistic translations, predictive validity, or establishing the minimal clinically important difference threshold, defined as smallest amount an outcome or measure is perceived as a meaningful change to patients). The PROMs were categorized into three groups based on the manifestations of disease of the population for which they were developed. The overall validity of each PROM was assessed across three stages of validation including content validity (phase 1); construct validity, reliability, and responsiveness (phase 2); and expansion of the validation evidence base (phase 3).
RESULTS: Of 2338 unique studies screened, 112 studies (4.8%) met inclusion criteria. The eight disease-specific PROMs identified were categorized into three groups: (1) overall chronic venous disease (C1 to C6); (2) C1 to C4 disease; and (3) C5 to C6 disease. Assessed by group, the Chronic Venous Insufficiency Questionnaire met criteria for validation at all three phases for patients with C1 to C4 disease, and the Charing Cross Venous Ulcer Questionnaire met criteria for validation at all three phases for patients with C5 to C6 disease. There were no PROMs that met all criteria for validation for use in overall chronic venous disease (C1 to C6).
CONCLUSIONS: Of the eight PROMs assessed in this review, only two met prespecified criteria at each phase for validation. The Chronic Venous Insufficiency Questionnaire and Charing Cross Venous Ulcer Questionnaire should be considered for use in patients with chronic venous disease without venous ulcers and with venous ulcers, respectively.
PCT No. PCT/GB95/01859 Sec. 371 Date Feb. 26, 1997 Sec. 102(e) Date Feb. 26, 1997 PCT Filed Aug. 7, 1995 PCT Pub. No. WO96/04890 PCT Pub. Date Feb. 22, 1996The invention provides an aqueous formulation comprising a pharmaceutically active agent present within vesicles suspended in an aqueous carrier. The invention resides in the finding that improved therapeutic efficacy can be achieved by providing the active agent both in the vesicles themselves and in the aqueous carrier vehicle. The invention provides a formulation which comprises: an aqueous vehicle; vesicles suspended in the aqueous vehicle; and a pharmaceutically active agent comprised within both the vesicles and the aqueous vehicle.
Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
Patients allocated to the conservative strategy will have the ECMO blender oxygen fraction (FbO2) will be titrated to achieve a post-oxygenator saturations of 92-96% (the FbO2 cannot be reduced to lower than 0.5). Post-oxygenator arterial blood gases (ABG's) will be taken to ensure safety and to allow for adjustments to be made. The ventilator FiO2 will be titrated to patient oxygen saturations (SpO2) of 92-96%.
Treatment with NITYR may cause elevated plasma tyrosine levels in patients with HT-1. Inadequate restriction of tyrosine and phenylalanine intake can lead to elevations in plasma tyrosine levels and levels greater than 500 micromol/L may lead to the following:

  * Ocular signs and symptoms including corneal ulcers, corneal opacities, keratitis, conjunctivitis, eye pain, and photophobia. All of which have been reported in patients treated with nitisinone [see Adverse Reactions (6.1)]. In a clinical study in a non HT-1 population without dietary restriction and reported tyrosine levels > 500 micromol/L both symptomatic and asymptomatic keratopathies have been observed. Therefore, perform a baseline ophthalmologic examination including slit-lamp examination prior to initiating NITYR treatment and regularly thereafter. Patients who develop photophobia, eye pain, or signs of inflammation such as redness, swelling, or burning of the eyes or tyrosine levels are > 500 micromol/L during treatment with NITYR should undergo slit-lamp reexamination and immediate measurement of the plasma tyrosine concentration.
  * Variable degrees of intellectual disability and developmental delay. In patients treated with NITYR who exhibit an abrupt change in neurologic status, perform a clinical laboratory assessment including plasma tyrosine levels.
  * Painful hyperkeratotic plaques on the soles and palms.



Maintain concomitant reduction in dietary tyrosine and phenylalanine while on NITYR treatment. In patients with HT-1 who are treated with NITYR and dietary restriction and develop elevated plasma tyrosine levels, assess dietary tyrosine and phenylalanine intake. Do not adjust NITYR dosage in order to lower the plasma tyrosine concentration. Maintain plasma tyrosine levels below 500 micromol/L.
The onset of chronic diseases in childhood represents a stressful event for both young patients and their caregivers. In this context, coping strategies play a fundamental role in dealing with illness-related challenges. Although numerous studies have explored coping strategies employed by parents of children with chronic diseases, there remains a gap in the understanding of children's coping strategies and their correlation with their and their parents' anxiety. This study aims to investigate coping strategies and their interaction with anxiety in groups of young patients with cancer, type 1 diabetes (T1D), and their respective caregivers, in comparison to healthy children and caregivers. We recruited a total of 61 control children, 33 with cancer, and 56 with T1D, 7 to 15 years old, along with their mothers. Each participant completed a customized survey and standardized questionnaires. No significant differences emerged in coping strategies used by children among the different groups. However, when examining the association between coping strategy and anxiety, we found specific patterns of interaction between children's use of coping strategies and their and their mothers' anxiety levels. This study underscores the importance of an illness-specific approach to gain deeper insights into this topic and develop targeted interventions aimed at enhancing the psychological well-being of these vulnerable populations.
NEW MATERIAL:The compound of formula I (R<1> and R<2> are H or 1-4C alkyl) or its salt. USE:A cardiotonic agent acting directly to the heart and strengthen its contraction force, and useful for the remedy of cardiac insufficiency. It has high activity and excellent durability of the action. PROCESS:The compound of formula I can be prepared by (1) reacting the compound of formula II with triphenyl phosphine in a solvent such as N,N'-dimethylformamide, tetrahydrofuran, etc. at room temperature -150 deg.C, and (2) reacting the resultant compound of formula III with the compound of formula IVin the presence of a strong base such as 1,8-diazabicyclo[5,4,0]undec-7-ene, sodium alkoxide or sodium hydroxide, etc. at room temperature -150 deg.C.
The technical problem to be solved by the invention is to provide a wall breaking technology which has high wall breaking rate, low cost, no solvent residue and no damage to active ingredients, so as to solve the problems existing in the prior technical means. The technical principle is as follows: 1. pressurizing: the ganoderma lucidum spores are heated to 50 ℃ by microwaves, and the internal pressure of the spores is increased. Microwave irradiation causes polar substances, especially water molecules in ganoderma spores to absorb microwave energy to generate a large amount of heat, so that the internal temperature is increased, the internal pressure is increased, and the cell membranes and cell walls cannot be broken by the internal pressure at the moment. 2. And (3) reducing pressure: the external environmental pressure of the spore is gradually reduced to 0.5 atmospheric pressure, the air pressure difference is formed inside and outside the spore, and the effective components break through cell membranes and cell walls. Like a rubber balloon, the skin is very tough. Firstly, blowing air into the balloon, pressurizing the interior of the balloon, then placing the balloon bound with the opening into a sealed box, pumping and adjusting the air in the sealed box, and depressurizing the exterior. The balloon is easily ruptured under the large pressure differential created by the internal pressurization and external depressurization.
The invention relates to the field of cosmetology, in particular to agents for hair removal. The technical result of the claimed invention consists in the removal of at least 95% of hair with the root, without pain or with significantly decreased pain sensations during epilation, and in significant suppression of hair growth up to and including its complete disappearance when the claimed agent is applied multiple times. The claimed technical result is achieved in that the agent for hair removal comprises two compositions for sequential use, specifically a composition for pretreatment of the skin and a composition comprising an active component. According to the invention, the composition for pretreatment of the skin comprises at least one substance having a keratolytic effect, selected from the group consisting of a hydroxy acid and a hydroxy acid sodium salt, in a quantity of not more than 12 wt%, and/or a substance having a denaturing effect selected from the group consisting of carbamide and a guanidine salt, in a quantity of 2 to 30 wt%. The composition having an active component is in the form of a gel based on at least one polymer selected from a group consisting of polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid and polyacrylamide in a quantity of 12 to 18 wt%. The composition having an active component comprises at least one depilatory compound in a quantity of 1.5 to 16 wt%.
Three doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 4, and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
The invention discloses a drug for treating burn. The drug comprises 40-50g of lithospermum, 5-10g of dandelion, 3-15g of realgar, 20-30g of myrrh, 30-40g of raw dahurian angelica root and 20-35g of frankincense. The drug is ointment, is prepared from easily available and cheap raw materials and can be prepared by simple processes. The drug can be smeared on affected parts easily, protect wounds and promote wound healing and has effects of sterilization and disinfection. The gauze prepared from the drug is subjected to sterilization and then is used for dressing change after an anorectal disease operation. The drug has substantial curative effects of treating and healing burn, ulcer, eczema, and liver damage caused by an anorectal disease operation. The drug has definite therapeutic effects, is convenient for use, produces effects fast and is safe and painless.